Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLI-F06 dose regimen for scar improvement
NCT05501327Phase 2Unknown
- Sponsor
- Scarless Laboratories, Inc.
- Start
- Jul 2022
- Primary completion
- Jul 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SLI-F06 in cicatrix (3 cohorts), sponsored by Scarless Laboratories, Inc. Primary endpoint: Change in Scarless Labs Observer Scale at 9 months. Status: unknown.
02
Drugs
SLI-F06
03
Conditions
cicatrix
Beyond the preview
Go deeper on NCT05501327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05501327.